Prefilled syringes (PFS) have rapidly become one of the most influential formats in injectable drug delivery, driven
by demand for patient-friendly, ready-to-use drug-device combination products. PCI Pharma Services has positioned itself at the forefront of this transformation with major global investments in sterile fill-finish, assembly, testing and packaging. International Biopharmaceutical Industry (IBI) sat down with Dawn Manley, Director of Global Technical Sales, to discuss why PFS are surging, what biopharma companies need from partners today and how PCI is building an integrated, future-ready global network.

Prefilled syringes have seen remarkable growth in recent years. What’s driving this shift across clinical and commercial programmes?

The rise of prefilled syringes has been incredibly fast and it’s rooted in a fundamental shift toward patient-centric drug delivery. In clinical trials, PFS eliminate preparation steps and reduce product waste, which simplifies site workflows and improves dosing accuracy. Those advantages translate directly to the commercial world, where ease of administration, safety and reliability are paramount, especially as more therapies move into at-home self-injection.

We’re also seeing a strong push from biologics and biosimilars developers, where convenient and user-friendly delivery is a key differentiator. Combined with the growing prevalence of chronic disease, the market trajectory is clear; analysts project the global PFS market to more than double to over USD 16 billion by 2030. It’s one of the most dynamic segments in drug delivery today.